Retatrutide vs Tirzepatide vs Semaglutide: 2026 Head-to-Head Data Compared | Peptadex

Three GLP-1 Receptor Agonists, Three Different Approaches

The comparison of retatrutide vs tirzepatide vs semaglutide is now possible with real Phase 3 clinical data for all three drugs. With retatrutide's TRIUMPH-4 trial reporting 28.7% body weight loss in early 2026, we can finally stack these three leading weight loss peptides against each other using evidence, not speculation.

Each drug targets different combinations of receptors, producing distinct efficacy and safety profiles. This guide presents the data as reported in peer-reviewed clinical trials.

Mechanism of Action: Single, Dual, and Triple Agonists

Semaglutide (Ozempic/Wegovy)

Semaglutide is a single-agonist GLP-1 receptor agonist. It mimics the incretin hormone GLP-1, slowing gastric emptying, reducing appetite, and enhancing insulin secretion. Available as both injectable (Wegovy) and oral (Rybelsus/oral Wegovy) formulations.

Tirzepatide (Mounjaro/Zepbound)

Tirzepatide is a dual-agonist targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The addition of GIP activity appears to enhance weight loss beyond what GLP-1 alone achieves, potentially through improved fat metabolism and distinct central nervous system effects.

Retatrutide (LY3437943)

Retatrutide is a triple-agonist targeting GLP-1, GIP, and glucagon receptors. The glucagon receptor component is believed to increase energy expenditure and promote hepatic fat oxidation, producing the highest weight loss numbers seen in any obesity trial to date.

Weight Loss Results: Phase 3 Data Compared

Metric	Semaglutide 2.4mg	Tirzepatide 15mg	Retatrutide 12mg
Avg Weight Loss (%)	~15-17%	~20-22%	28.7%
Trial Duration	68 weeks	72 weeks	68 weeks
Key Trial	STEP program	SURMOUNT program	TRIUMPH-4
FDA Status	Approved	Approved	Phase 3 (not approved)
Administration	Weekly injection or daily oral	Weekly injection	Weekly injection

A head-to-head NEJM study comparing tirzepatide directly against semaglutide demonstrated that tirzepatide produced approximately 40-50% more weight loss than semaglutide at maximum doses. Retatrutide's Phase 3 numbers suggest an even larger margin over both competitors, though direct head-to-head trials between retatrutide and tirzepatide have not been conducted.

Beyond Weight Loss: Additional Clinical Benefits

Cardiovascular

Semaglutide has an FDA-approved indication for reducing cardiovascular death, heart attack, and stroke risk in adults with CVD and obesity. Tirzepatide's cardiovascular outcomes data is still being collected. Retatrutide showed reductions in non-HDL cholesterol and systolic blood pressure in TRIUMPH-4.

Type 2 Diabetes

All three drugs lower HbA1c effectively. Retatrutide reduced HbA1c by 1.7-2.0% in its Phase 3 diabetes trial. Semaglutide and tirzepatide both have established T2D indications.

Osteoarthritis Pain

Retatrutide is unique in demonstrating significant relief from osteoarthritis knee pain in TRIUMPH-4, with WOMAC pain score reductions of up to 75.8%. This dual benefit of weight loss plus pain relief has not been a primary endpoint in semaglutide or tirzepatide obesity trials.

Safety and Side Effects

All three drugs share common gastrointestinal side effects including nausea, vomiting, and diarrhea. However, there are differences worth noting:

• Semaglutide: Well-characterized safety profile after years of market use. GI side effects are the primary concern. The new 7.2mg dose launched in April 2026 for patients tolerating 2.4mg.
• Tirzepatide: Similar GI profile to semaglutide. Post-marketing surveillance continues to build the long-term safety picture.
• Retatrutide: A notable new safety signal emerged in Phase 3: dysesthesia (unusual skin sensations) occurred in up to 20.9% of patients on the 12mg dose, compared to 0.7% with placebo. This will be a key factor in FDA review.

Availability and Cost

As of April 2026, semaglutide and tirzepatide are both FDA-approved and commercially available. Retatrutide remains investigational with seven additional Phase 3 readouts expected throughout 2026. An FDA submission for retatrutide has not yet occurred.

For a detailed side-by-side comparison of semaglutide and tirzepatide, visit our comparison tool.

Key Takeaways

• Retatrutide's triple-agonist mechanism produced the highest weight loss in Phase 3 trials (28.7%), followed by tirzepatide (~20-22%) and semaglutide (~15-17%).
• More receptor targets correlate with greater weight loss but also introduce unique safety signals (dysesthesia for retatrutide).
• Semaglutide has the longest track record and broadest approved indications including cardiovascular risk reduction.
• Retatrutide is not yet FDA-approved and remains investigational.
• Direct head-to-head trials between retatrutide and tirzepatide have not been conducted.

Disclaimer: This article is for educational and informational purposes only. It is not medical advice and should not be used to make treatment decisions. Weight loss results in clinical trials may not reflect individual outcomes. Always consult a qualified healthcare provider before starting or switching any medication. Peptadex does not sell peptides or endorse any specific products or vendors.